{"id":499665,"date":"2020-08-01T00:00:00","date_gmt":"2020-07-30T13:30:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499665"},"modified":"2020-07-30T13:30:03","modified_gmt":"2020-07-30T13:30:03","slug":"uveitis-emerging-drugs-and-key-players-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/uveitis-emerging-drugs-and-key-players-delveinsight_499665.html","title":{"rendered":"Uveitis Emerging Drugs and Key Players | DelveInsight"},"content":{"rendered":"
\"Uveitis<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
Uveitis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Uveitis market. A detailed picture of the Uveitis pipeline landscape is provided, which includes the disease overview and Uveitis treatment guidelines. <\/div>\n

Uveitis is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as specific white blood cells rush to the affected part.<\/p>\n

Launch of emerging therapies, such as Sirolimus (for Non-Infectious Uveitis of the Posterior Segment (NIU-PS)), EGP-437 (for Non-Infectious Anterior Uveitis), Sarilumab (for Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)), and LME636 ( Anterior Acute Uveitis), shall further create a positive impact on the market.<\/p>\n

Sirolimus (Opsiria, Santen) is a macrolide compound derived from Streptomyces hygroscopicus.It has a potent immunosuppressive and antineoplastic activity that depends on its binding to specific cytosolic proteins (immunophilins) to generate an immunosuppressive complex. Sirolimus inhibits the activity of the serine\/threonine-protein kinase of the mammalian target of rapamycin (mTOR).<\/p>\n

The phase III SAKURA 1 and 2 studies reported significant improvement in reducing ocular inflammation in patients with active noninfectious uveitis and successful tapering of corticosteroid dose (<\/p>\n

Iontophoresis is a noninvasive method in which low electrical current is applied to an ionizable substance to increase its mobility across a surface through electrochemical repulsion. Sarilumab is under the development by Sanofi Aventis. The therapeutic candidate is in Phase II stage of development for the treatment of Uveitis. It is also approved for the treatment of Rheumatoid arthritis. The therapeutic candidate acts by binding to the Interleukin-6 Receptor.<\/p>\n

 <\/p>\n

The launch of the emerging therapies is expected to significantly impact the Uveitis treatment scenario in the upcoming years:-
Drugs covered
1. ADX-102
2. Sirolimus
And many others<\/p>\n

\n

The key players in Uveitis market are:
1. Aldeyra Therapeutics Inc
2. Santen
And many others<\/p>\n

 <\/p>\n

Scope of Uveitis Report<\/a><\/p>\n